Company Overview

Inspire Medical Systems, Inc. is a U.S.-based medical technology company focused on the development and commercialization of implantable neurostimulation solutions for patients with moderate to severe obstructive sleep apnea (OSA). The company operates within the medical devices and sleep disorder treatment industries, addressing a large patient population that is unable to tolerate or benefit from continuous positive airway pressure (CPAP) therapy.

The company’s primary product is the Inspire therapy system, an implantable hypoglossal nerve stimulation device designed to maintain an open airway during sleep. Inspire targets adult OSA patients who meet specific clinical criteria and are seeking an alternative to traditional treatments. Founded in 2007, the company evolved from early-stage neurostimulation research into a commercial-stage medical device manufacturer following U.S. regulatory approvals and reimbursement expansion, culminating in its initial public offering in 2018.

Business Operations

Inspire Medical Systems generates revenue primarily through the sale of the Inspire therapy system, which includes an implantable neurostimulator, sensing lead, stimulation lead, and a patient-controlled remote. Revenue is driven by device sales to hospitals and outpatient surgical centers, as well as recurring revenue from device replacements and related components. The company operates as a single-reportable segment focused on upper airway stimulation therapy for sleep apnea.

Operations include research and development, clinical education, physician training, sales, and post-implant patient support. Manufacturing is conducted through third-party contract manufacturers, while the company maintains internal control over product design, quality systems, and regulatory compliance. Inspire collaborates closely with sleep physicians, otolaryngologists, and hospital systems but does not disclose material joint ventures; its operations are conducted primarily through wholly owned subsidiaries.

Strategic Position & Investments

Strategically, Inspire Medical Systems is focused on expanding adoption of hypoglossal nerve stimulation as a standard-of-care alternative for CPAP-intolerant OSA patients. Growth initiatives include expanding physician training programs, increasing direct-to-consumer awareness, and driving broader insurance coverage and reimbursement adoption. The company has emphasized disciplined clinical evidence generation to support long-term market penetration.

Inspire continues to invest heavily in research and development to enhance device performance, improve patient outcomes, and streamline implantation procedures. While the company has not pursued large-scale acquisitions, it invests in next-generation device platforms, digital health integration, and international market expansion. Data inconclusive based on available public sources regarding material equity investments in external portfolio companies.

Geographic Footprint

Inspire Medical Systems is headquartered in North America (United States), with its principal executive offices located in Minnesota. The United States represents the company’s largest and most established market, supported by widespread reimbursement coverage and a growing network of trained implanting physicians.

Internationally, Inspire has expanded its commercial presence across Europe, including key markets such as Germany, United Kingdom, and France, supported by regulatory approvals and selective reimbursement frameworks. The company also reports early-stage commercial and clinical activity in parts of Asia-Pacific, with international operations contributing an increasing but still minority share of total revenue.

Leadership & Governance

Inspire Medical Systems was founded by a group of medical device entrepreneurs and clinicians with expertise in neurostimulation and sleep medicine. The leadership team emphasizes evidence-based medicine, long-term clinical outcomes, and disciplined commercial execution as core elements of its strategic vision.

Key executives include:

• Timothy J. Herbert – President and Chief Executive Officer
• Vance Brown – Chief Financial Officer
• Ashley McEvoy – Chief Operating Officer
• Steve Calhoun – Chief Commercial Officer
• Jason Olson – Chief Technology Officer

The company operates under a board-governed structure typical of U.S. publicly traded medical device firms, with oversight of strategy, risk management, and regulatory compliance aligned with long-term shareholder and patient interests.